What this covers
Lysosomal storage diseases are a group of rare inherited disorders in which the lysosomes — the cell's recycling centres — cannot break down waste, which then builds up and damages organs. This review looks at how gene therapy is being developed to treat these conditions, with a particular focus on metachromatic leukodystrophy (MLD) and mucopolysaccharidosis type I (MPS-I). It explains why existing options such as enzyme replacement therapy and stem cell transplant have limits, and how correcting the faulty gene might do better.
Key takeaways
- Intravenous enzyme replacement therapy can protect the internal organs but does not reach the brain, so it cannot prevent damage to the nervous system.
- Haematopoietic stem cell transplant has important limitations for early-onset forms unless it is carried out before the disease begins.
- Gene therapy that corrects a patient's own blood stem cells could allow supra-normal production of the missing enzyme and help correct cells across many tissues, including the central nervous system.
Why it matters
Because current treatments struggle to protect the brain, gene therapy offers a promising route to tackle both the internal and neurological effects of these diseases — potentially changing how MLD and MPS-I are treated.
